Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Peripherally Inserted Central Catheters Market, by Product Type (Single Lumen, Double Lumen, and Multi Lumen), by End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Catheterization Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 857.7 million in 2021 and is expected to exhibit a CAGR of 6.9% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Global Peripherally Inserted Central Catheters Market- Impact of Coronavirus (COVID-19) Pandemic

Lockdown in various countries due to the pandemic has placed an economic burden on the private healthcare sector. Healthcare providers are facing shortage of raw materials required for the production of health supplements including eye health supplements, across the globe. Many manufacturers are facing issues such as shortage of labor and transportation of raw materials, which has affected the production of the peripherally inserted central catheters. Most of the vehicles used for transportation of these products are stuck at the state borders or at the country’s borders. For instance, in July 2020, the Society for Vascular Surgery published a protocol for central venous access in patients with coronavirus (COVID-19), in the Elsevier, a Dutch publishing and analytics company which specializes in technical, scientific, and medical content.

Similarly, on May 28, 2020, a group of experts from the Italian association GAVeCeLT (Gruppo Accessi Venosi Centrali a Lungo Termine) provided recommendations for using vascular access in COVID-19 patients. The recommendations included selection, insertion, and maintenance of venous access devices, developed to protect the operator and reduce the risk of infection. Following are the recommendations provided by the experts from GAVeCeLT for choosing the appropriate central venous catheters, insertion technique, and precautions to avoid operator contamination:

  • Usage of a central venous access (peripherally inserted central catheters (PICC), femorally inserted central catheter (FICC), or centrally inserted central catheter (CICC) is recommended for COVID-19 patients in the Intensive Care Units (ICU)
  • Femoral access should be considered to avoid the risk of operator contamination by the patient’s oral, nasal, and tracheal secretions during insertion
  • Usage of ultrasound guidance through wireless ultrasound probes for the insertion of any central venous access or midline catheter or peripheral arterial catheter is recommended in order to avoid risk of contamination
  • Adopt the standard barrier precautions such as skin antisepsis with 2% chlorhexidine in 70% isopropyl alcohol, non-sterile surgical mask, non-sterile cap, sterile gloves, waterproof sterile gown, and others for patient protection
  • Adopt the standard personal protective equipment (double glove, full suit, goggles or face shield, and footwear) for protection of the operator

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global peripherally inserted central catheters market during the forecast period.

The increasing number of product approvals from Egyptian regulatory bodies is expected to drive the growth of the global peripherally inserted central catheters market during the forecast period. For instance, in October 2018, Bactiguard received approval from the Egyptian Ministry of Health for BIP Foley, a urinary catheter.

The increasing number of dialysis procedures performed in Africa is expected to drive the global peripherally inserted central catheters market growth over the forecast period. For instance, according to South African Renal Registry annual report 2016, around 3,175 patients were receiving dialysis treatment in the public sector in South Africa and 881 (27.8%) were undergoing peritoneal dialysis, in 2016.

The increasing number of tenders for Bactiguards’s anti- infective central venous catheters (BIP CVC) products is expected to drive the global peripherally inserted central catheters market growth. For instance, in July 2018, Bactiguard won a Swedish tender, which covered the Skåne region. The tender enables hospitals in Skåne region to purchase Bactiguard’s anti-infective central venous catheters (BIP CVC) for at least two years, effective from October 2018 to October 2020.

Increasing prevalence of cancer in the U.S. is expected to drive the segment growth over the forecast period. For instance, according to the Cancer Atlas, by American Cancer Society, around 1.3 million new cases of cancer were diagnosed while around 666,000 cancer deaths occurred in Latin America and the Caribbean in 2018.

Browse 39 Market Data Tables and 32 Figures spread through 264 Pages and in-depth TOC on Global Peripherally Inserted Central Catheters Market, by Product Type (Single Lumen, Double Lumen, and Multi Lumen), by End User (Hospital & Clinics, Ambulatory Surgical Centers, and Catheterization Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2028"

To know the latest trends and insights related to Global Peripherally Inserted Central Catheters Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/peripherally-inserted-central-catheters-market-4048

The increasing inorganic growth strategies by key players is expected to drive the growth of global peripherally inserted central catheters market. For instance, in March 2018, Bactiguard announced that it entered into a distribution agreement with Ecomed Services NV, a distributor of medical devices in Belgium and the Netherlands, for the commercialization and distribution of Bactiguard products of catheters in the Netherlands and expand its European coverage.

Key Takeaways of the Global Peripherally Inserted Central Catheters Market:

  • The global peripherally inserted central catheters market is expected to exhibit a CAGR of 6.9% during the forecast period (2021-2028) owing to the increasing research and development activities conducted by academic researchers is anticipated to provide lucrative growth opportunities for players in the global peripherally inserted central catheters market. For instance, in August 2019, researchers from neonatal intensive care unit (NICU), General Hospital ‘Agios Panteleimon,’ Greece, and Royal Alexandra Children’s Hospital, Brighton, U.K., reported that the incidence of complications associated with the use of umbilical venous catheters and peripherally inserted central catheters in very low birth weight infants did not significantly differ in the study.
  • Among product type segment, multi lumen segment will hold the largest segment compared to other, due to increasing drug launches, key players in the market are also launching new products in market, which is expected to fuel the multi lumen segment growth in the global peripherally inserted central catheters market. For instance, in 2015, Teleflex Incorporated, global provider of medical technology products, launched triple-lumen version of unique Arrow PICC with Chlorag+ard Technology (antimicrobial and antithrombogenic) (offered by Teleflex Incorporated) to significantly reduce the risk of central line-associated bloodstream infections (CLABSI) and PICC-related vessel thrombosis.
  • Major players operating in the global peripherally inserted central catheters market include: AngioDynamics Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, Teleflex Incorporated, Argon Medical Devices, Inc., Cook Medical Inc., ICU Medical, Inc., Medical Components, Inc., Access Vascular, and Vygon (UK) Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.